Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide-Reference-Cited by-同舟云学术

Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide

Published:2019-05-11 Issue:2 Volume:38 Page:299-310
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Megías Javier^ORCID,Martínez Alba,San-Miguel Teresa,Gil-Benso Rosario,Muñoz-Hidalgo Lisandra,Albert-Bellver David,Carratalá Amara,Gozalbo Daniel,López-Ginés Concha,Gil María Luisa,Cerdá-Nicolás Miguel

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00788-2.pdf

Reference51 articles.

1. Holland EC (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 97:6242–6244

2. Damodaran O, van Heerden J, Nowak AK, Bynevelt M, McDonald K, Marsh J, Lee G (2014) Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. J Clin Neurosci 21:478–481

3. Yan K, Yang K, Rich JN (2013) The evolving landscape of glioblastoma stem cells. Curr Opin Neurol 26:701–707

4. Jackson M, Hassiotou F, Nowak A (2015) Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis 36:177–185

5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinin B1 receptor and TLR4 interaction in inflammatory response;Inflammation Research;2024-07-04

2. Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy;Cancer Cell International;2022-10-27

3. Combination therapy with interferon-gamma as a potential therapeutic medicine in rat's glioblastoma: A multi-mechanism evaluation;Life Sciences;2022-09

4. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma;Journal of Hematology & Oncology;2021-10-29

5. Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment;Cancer Investigation;2021-07-19